Androgen News and Research RSS Feed - Androgen News and Research

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

Study: Common prostate cancer therapy exposes low-risk patients to more adverse side effects

A common prostate cancer therapy should not be used in men whose cancer has not spread beyond the prostate, according to a new study led by researchers at Henry Ford Hospital. [More]
Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the December 3 issue of JAMA. [More]
Exome sequencing refines 46,XY DSD diagnosis

Exome sequencing refines 46,XY DSD diagnosis

Exome sequencing can identify a likely genetic cause of 46,XY disorders of sex development in about a third of cases, report researchers. [More]
Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation. [More]
Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. [More]
ProstaCaid dietary supplement supports prostate health

ProstaCaid dietary supplement supports prostate health

A recent presentation at an international cancer research conference in Greece reviewed the body of data on ProstaCaid, a dietary supplement compound for prostate health. A number of published studies demonstrate the formula's effects in supporting prostate health against specific prostate cancer cell lines and prostate urinary symptoms. [More]
Study: Certain prostate cancer medications linked to cardiac death risk

Study: Certain prostate cancer medications linked to cardiac death risk

A new study has found that certain prostate cancer medications are linked with an increased risk of dying from heart-related causes in men with congestive heart failure or prior heart attacks. Published in BJU International, the findings will help doctors and patients weigh the benefits and risks of the drugs. [More]
New combination therapy shows promise in treating prostate cancer

New combination therapy shows promise in treating prostate cancer

Like discriminating thieves, prostate cancer tumors scavenge and hoard copper that is an essential element in the body. But such avarice may be a fatal weakness. [More]
Endocrine Society issues updated Clinical Practice Guideline on androgens in women

Endocrine Society issues updated Clinical Practice Guideline on androgens in women

The Endocrine Society today issued a Clinical Practice Guideline (CPG) advising against the use of testosterone therapy in healthy women. [More]
Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

Phase 3 COU-AA-302 results show ZYTIGA plus prednisone prolongs overall survival in men with chemotherapy-naive mCRPC

A final analysis of the Phase 3 COU-AA-302 trial presented today at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, Spain showed that ZYTIGA® (abiraterone acetate) plus prednisone significantly prolonged overall survival (OS), compared to an active control of placebo plus prednisone, in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). [More]
Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer, Orion begin patient enrollment in ODM-201 Phase III trial for castration-resistant prostate cancer

Bayer HealthCare and Orion Corporation, a pharmaceutical company based in Espoo, Finland, have begun to enroll patients in a Phase III trial with ODM-201, an investigational oral androgen receptor inhibitor in clinical development. [More]

Low free testosterone predicts prostate cancer reclassification

Lower levels of free testosterone predict an increased likelihood of disease reclassification in men with prostate cancer, researchers report. [More]
Study reveals treatment trends for prostate cancer in Japan

Study reveals treatment trends for prostate cancer in Japan

There has been a recent increase in use of radiotherapy in Japanese men newly diagnosed with prostate cancer and a concomitant decrease in use of androgen deprivation therapy, study findings indicate. [More]
Scientists identify mechanism by which inherited neurological disease causes muscle weakness in men

Scientists identify mechanism by which inherited neurological disease causes muscle weakness in men

Researchers at University of California, San Diego School of Medicine have identified the mechanism by which a rare, inherited neurodegenerative disease causes often crippling muscle weakness in men, in addition to reduced fertility. [More]
Study takes stock of current sexual verification policies in athletics

Study takes stock of current sexual verification policies in athletics

Spanish hurdler Mar-a Jos- Mart-nez-Pati-o, who in the 1980s endured harsh global media attention when she was subjected to unscientific gender tests, is co-author of a study that takes stock of current sexual verification policies in athletics. [More]
Childhood obesity linked to early puberty

Childhood obesity linked to early puberty

A new link has been identified between obesity in childhood and the lowering of the age of puberty. [More]
Research roundup: ACA lawsuit primer; ACA strategies in 4 states; competitive plans for those eligible for Medicare and Medicaid

Research roundup: ACA lawsuit primer; ACA strategies in 4 states; competitive plans for those eligible for Medicare and Medicaid

In 2012, the U.S. Supreme Court upheld the constitutionality of the ACA, but that did not end attacks against the law. Since the decision in National Federation of Independent Business v. Sebelius, objecting parties have filed more than 100 cases in federal courts nationwide. [More]
Letrozole drug results in higher birth rates in women with PCOS

Letrozole drug results in higher birth rates in women with PCOS

The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn State College of Medicine researchers. [More]
Men with prostate cancer achieve stronger muscles and remain active through playing football

Men with prostate cancer achieve stronger muscles and remain active through playing football

Men with prostate cancer aged 43‒74 achieve bigger and stronger muscles, improve functional capacity, gain positive social experiences and the desire to remain active through playing football for 12 weeks. [More]

Androgen sensitivity may contribute to hypertrichosis in girls

Prepubertal girls with hypertrichosis are likely to have genetic variants of the androgen receptor known to be particularly sensitive to androgen, say researchers. [More]
Advertisement
Advertisement